How to present pharmacovigilance experience safely and clearly

Identify the safety workstream

State whether the work involved individual case safety reports, literature, signal management, aggregate reports, risk-management plans, safety systems, agreements, audits, inspections or safety governance. Add development or post-authorisation context and jurisdictional scope where appropriate.

Do not compress all safety activity into pharmacovigilance strategy. Processing, medical review, analysis, writing, quality oversight and accountable sign-off are distinct contributions, and each can provide strong evidence when described accurately.

Explain the controlled decision

Describe the issue at a non-identifying level, the information available, your responsibility and the procedure followed. For signal work, distinguish detection, validation, analysis, recommendation and final governance decision. For cases, distinguish receipt, assessment, follow-up, coding, quality review and submission.

Include timeliness and quality only where supported. A useful result might be an escalated issue assessed, an aggregate report delivered, a process corrected or an inspection response completed. Never include identifiable patient information in an application or interview example.

Show benefit-risk and escalation awareness

EMA describes pharmacovigilance as ongoing throughout use of a medicine because information continues to emerge after authorisation. Candidates should show how their work fitted the wider benefit-risk system rather than treating an individual task as isolated administration.

Explain when you escalated, which governance body considered the matter and how action was documented. If another role held accountable medical judgement, name your contribution without claiming the final decision.

Demonstrate systems and quality work

For operational or quality roles, describe data flow, reconciliation, controlled documents, training, vendor oversight, deviations, corrective actions or inspection readiness. Connect the system improvement to a safety obligation or reliability outcome rather than listing software names.

For leadership, show how workload, compliance risk, partner obligations and medical priorities were balanced. Include development of team capability and governance where it formed part of the role.

Prepare an interview-safe example

Use a sanitised structure: product stage and broad context; safety process; your authorised role; evidence considered; escalation or action; documented outcome; and learning. Decide beforehand which details cannot be disclosed and explain that boundary confidently.

Check the target role carefully. Case operations, safety science, QPPV-office work, systems, epidemiology and risk management overlap but are not interchangeable. Make direct experience, transferable experience and development gaps visible.

A confidentiality-safe evidence template

Record development or post-authorisation stage, broad product scope, safety process, your authorised role, non-identifying issue, evidence considered, escalation route, controlled action and verified outcome. Remove patient identifiers and restricted assessment details.

Ask whether the example demonstrates medical judgement, scientific analysis, operational delivery, systems quality or governance. Use the accurate category so a strong contribution is not weakened by claiming accountability held by another role.

Sources and further reading

Authoritative sources support the regulated or employment context. The practical framework and interpretation are original PTTF editorial work.

1. Pharmacovigilance overview — European Medicines Agency
2. Risk management plans — European Medicines Agency